Translational Development Acquisition Corp.
TDAC
$10.88
$0.040.32%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 199.00% | -19.06% | 21.66% | 248.61% | 12,905.88% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 199.00% | -19.06% | 21.66% | 248.61% | 12,905.88% |
| Operating Income | -199.00% | 19.06% | -21.66% | -248.61% | -12,905.88% |
| Income Before Tax | -41.66% | -10.13% | 20,048.75% | 2,808.16% | 95,588.24% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -41.66% | -10.13% | 20,048.75% | 2,808.16% | 95,588.24% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -41.66% | -10.13% | 20,048.75% | 2,808.16% | 95,588.24% |
| EBIT | -199.00% | 19.06% | -21.66% | -248.61% | -12,905.88% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -40.62% | -10.19% | 4,953.33% | 601.99% | 18,625.00% |
| Normalized Basic EPS | -38.23% | -10.17% | 4,766.67% | 598.95% | 15,533.33% |
| EPS Diluted | -40.62% | -10.19% | 4,953.33% | 601.99% | 18,625.00% |
| Normalized Diluted EPS | -38.23% | -10.17% | 4,766.67% | 598.95% | 15,533.33% |
| Average Basic Shares Outstanding | -1.82% | 0.00% | 304.20% | 440.93% | 440.93% |
| Average Diluted Shares Outstanding | -1.82% | 0.00% | 304.20% | 440.93% | 440.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |